These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39079152)

  • 1. Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis.
    Cirulli GO; Davis M; Stephens A; Chiarelli G; Finati M; Corsi N; Williams E; Affas R; Sood A; Buffi N; Lughezzani G; Carrieri G; Salonia A; Briganti A; Montorsi F; Rogers C; Abdollah F
    J Urol; 2024 Jul; ():101097JU0000000000004118. PubMed ID: 39079152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of type of definitive treatment on race-based differences in prostate cancer-specific survival.
    Frego N; Labban M; Stone BV; Koelker M; Alkhatib K; Lughezzani G; Buffi NM; Lipsitz SR; Weissman JS; Fletcher SA; Kibel AS; Trinh QD; Cole AP
    Prostate; 2023 Aug; 83(11):1099-1111. PubMed ID: 37150867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans.
    Sherer MV; Qiao EM; Kotha NV; Qian AS; Rose BS
    JAMA Oncol; 2022 Oct; 8(10):1471-1476. PubMed ID: 35925581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation.
    Kensler KH; Pernar CH; Mahal BA; Nguyen PL; Trinh QD; Kibel AS; Rebbeck TR
    J Natl Cancer Inst; 2021 Jun; 113(6):719-726. PubMed ID: 33146392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.
    Suresh T; Sharma J; Goel S; Kovac E; Gao Q; Gartrell B
    Clin Genitourin Cancer; 2019 Apr; 17(2):139-144. PubMed ID: 30655076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohort.
    Tinsley SA; Finati M; Stephens A; Chiarelli G; Cirulli GO; Williams E; Morrison C; Richard C; Hares K; Sood A; Buffi N; Lughezzani G; Bettocchi C; Salonia A; Briganti A; Montorsi F; Carrieri G; Rogers C; Abdollah F
    Cancer; 2024 Sep; 130(18):3157-3169. PubMed ID: 38804713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate Specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data.
    Alkhatib K; Labban M; Briggs L; Nguyen DD; Herzog P; Cole AP; Haag A; Trinh QD
    J Urol; 2022 May; 207(5):993-1000. PubMed ID: 34967663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study.
    Chinea FM; Patel VN; Kwon D; Lamichhane N; Lopez C; Punnen S; Kobetz EN; Abramowitz MC; Pollack A
    Oncotarget; 2017 Sep; 8(41):69709-69721. PubMed ID: 29050235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
    Dall'Era MA; deVere-White R; Rodriguez D; Cress R
    Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insufficient Lycopene Intake Is Associated With High Risk of Prostate Cancer: A Cross-Sectional Study From the National Health and Nutrition Examination Survey (2003-2010).
    Lu Y; Edwards A; Chen Z; Tseng TS; Li M; Gonzalez GV; Zhang K
    Front Public Health; 2021; 9():792572. PubMed ID: 34966715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of Ethnic Heterogeneity on Prostate Cancer Mortality After Radical Prostatectomy in Hispanic or Latino Men: A Population-based Analysis.
    Velasquez MC; Chinea FM; Kwon D; Prakash NS; Barboza MP; Gonzalgo ML; Ritch CR; Pollack A; Parekh DJ; Punnen S
    Urology; 2018 Jul; 117():108-114. PubMed ID: 29630954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
    de Vos II; Remmers S; Hogenhout R; Roobol MJ;
    Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
    Remmers S; Bangma CH; Godtman RA; Carlsson SV; Auvinen A; Tammela TLJ; Denis LJ; Nelen V; Villers A; Rebillard X; Kwiatkowski M; Recker F; Wyler S; Zappa M; Puliti D; Gorini G; Paez A; Lujan M; Nieboer D; Schröder FH; Roobol MJ
    Eur Urol; 2023 Nov; 84(5):503-509. PubMed ID: 37088597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of Image-Guided Targeted Prostate Biopsy Outcomes by PI-RADS® Score and Ethnicity in a Diverse, Multiethnic Population.
    Hines L; Zhu D; DeMasi M; Babar M; Chernyak V; Kovac EZ; Aboumohamed A; Sankin A; Agalliu I; Watts KL
    J Urol; 2021 Sep; 206(3):586-594. PubMed ID: 33881932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable prostate-specific antigen levels correlate with a worse prognosis in high-grade prostate cancer: a population-based analysis.
    Liu Z; Hong P; He J; Li Z; Wu J; Qiu L; Zhao Z; Lu J
    Int J Surg; 2024 Jun; ():. PubMed ID: 38935086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
    Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
    JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient perspectives of prostate cancer screening vary by race following 2018 guideline changes.
    Riviere P; Kalavacherla S; Banegas MP; Javier-Desloges J; Martinez ME; Garraway IP; Murphy JD; Rose BS
    Cancer; 2023 Jan; 129(1):82-88. PubMed ID: 36345568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
    Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
    Ann Oncol; 2017 May; 28(5):1098-1104. PubMed ID: 28453693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer.
    Iyer HS; Stone BV; Roscoe C; Hsieh MC; Stroup AM; Wiggins CL; Schumacher FR; Gomez SL; Rebbeck TR; Trinh QD
    JAMA Netw Open; 2024 Jun; 7(6):e2414582. PubMed ID: 38833252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.